Advancing Diagnosis and Treatment for Lung Cancer Patients Using Hybrid PET/MR Imaging and Novel Visualization Tools
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- University Hospital of North Norway
- Enrollment
- 35
- Locations
- 1
- Primary Endpoint
- Sensitivity and specificity of PET/MR vs. clinical routine PET/CT
- Status
- Terminated
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this project is to investigate if PET/MR imaging improves the accuracy in visualization and characterization of lung cancer disease, compared to PET/CT.
Detailed Description
Lung cancer is the most frequent cancer type and the leading cause of cancer-related death worldwide. Positron emission tomography (PET) coupled with computed tomography (CT) is the standard of care for visualization and staging of lung cancer. Recent clinical introduction of hybrid PET and magnetic resonance (MR) imaging systems has shown potential to improve tumor imaging beyond the limits of PET/CT. However, knowledge about the clinical impact of this new hybrid modality is still limited. This project aims to investigate how PET/MR may improve the diagnosis and treatment of lung cancer disease, compared to PET/CT: PET/MR may allow early detection of brain and liver metastases, which strongly affects treatment outcome and survival; predictive models based on machine learning may combine image derived biomarkers from PET/MR, histology and health record data, to automatically visualize and characterize the tumor, facilitating computer aided diagnosis and personalized radiotherapy treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Referred to clinical PET/CT examination for investigation of lung disease.
Exclusion Criteria
- •Blood glucose level \>8.3 mmol/l
- •MR incompatible objects, e.g. metal implants, inside the body
- •Intolerance to gadolinium-based contrast agents, e.g. severe renal disease (GFR\<30).
- •Unable to give written consent.
Outcomes
Primary Outcomes
Sensitivity and specificity of PET/MR vs. clinical routine PET/CT
Time Frame: 1-2 weeks after the initial inclusion.
Sensitivity and specificity of PET/MR scans will be compared with in clinical routine PET/CT examinations for lung cancer disease feature prediction.
Secondary Outcomes
- Prediction of treatment response and progression-free survival(5 years after inclusion.)